AI
By
Could AbbVie and IGI’s $1.9B Bet on AI-Engineered Trispecific Antibody Signal a New Era for Relapsed Myeloma Treatment?
Key Highlights: AbbVie Accelerates into AI-Powered Immuno-OncologyAbbVie has entered a global licensing agreement worth up to $1.925 billion…
Can Personalis and Tempus Leverage AI to Transform Cancer Recurrence Detection for 150,000 Colorectal Patients? Strategic Expansion Deepens MRD Leadership
Key Highlights AI at the Core of Next-Gen Recurrence MonitoringThe expansion of Personalis’ NeXT Personal® MRD test into…
Will AI-Powered Querent™ by Mango Sciences Transform Veeda Lifesciences’ Global Clinical Trial Efficiency?
Key Highlights AI-Driven Precision in Global Trial RecruitmentVeeda Lifesciences, a global CRO, has announced a strategic investment in…
Can Revolution Medicines and Iambic’s AI Alliance Accelerate the Discovery of Next-Gen Cancer Drugs Targeting RAS Mutations?
Key Highlights AI-Powered Discovery for RAS-Addicted CancersRevolution Medicines, a leader in targeting RAS-driven cancers, is turning to artificial…
Can Takeda and Nabla Bio’s $1 Billion AI Alliance Redefine the Future of Protein Therapeutics?
Key Highlights: AI Takes Center Stage in Takeda’s R&D RebootAfter narrowing its research focus to small molecules, biologics,…
Could Cohere’s New Paris Office Accelerate AI Adoption Across Europe’s Healthcare and Biopharma Sector?
Key Insights: Expanding Footprint in Europe Cohere, a Canadian AI firm known for developing large language models and…
